Pollen Extract for Hot Flashes

Purified pollen extract has not been shown to ease hot flashes reliably. In the main placebo-controlled trial, 64 menopausal women took a Swedish pollen and pistil formula or placebo for 3 months: 65% on the extract had fewer hot flushes compared with 38% on placebo (p<0.006), and diary counts fell 27% more than on placebo [1]. A smaller trial of the same extract, under its PureCyTonin name, in 39 breast cancer survivors reported fewer hot flashes than at the start, but its abstract gives no comparison with placebo [2][3].

Most of the other supportive data come from studies without a control group, which report large falls in hot flashes [4][5], by 48.5% in one [4]. When a 2024 meta-analysis pooled only the controlled studies, the benefit was no longer statistically significant, and its authors concluded the improvements in uncontrolled studies may have been a placebo effect [6]. The North American Menopause Society's 2023 position statement does not recommend pollen extract for hot flashes (Level III) [7].

The mechanism is not established. Researchers working on the purified cytoplasmic extract describe it as an SSRI-like therapy [9]; this is a proposed mechanism, not one shown in women. The pollen-pistil part of the Swedish formula contains high levels of superoxide dismutase, an antioxidant enzyme, and one study suggests antioxidant effects may play a role [10].

Laboratory analysis of the Swedish formula found only low, sub-effective amounts of the phytoestrogens daidzin, daidzein and genistin, and a high dose (500 mg/kg a day) caused no uterine growth in immature female rats [8]. In a test with human liver enzymes, the extract did not inhibit CYP2D6, the enzyme that converts tamoxifen to its active metabolites [11].

These are laboratory and animal findings. They make an estrogen-like effect, or interference with tamoxifen through CYP2D6, less likely, but they don't show that the extract relieves hot flashes, and they don't replace safety data in women with hormone-sensitive cancers.

The placebo-controlled trial used two tablets of the Swedish formula each morning for 3 months, after a 1-month run-in; the abstract does not give the tablet strength [1]. An open study of the same formula gave 160 mg of extract twice, with 5 mg of vitamin E, for 3 months [4]. Trials judged results after 2 to 3 months [1][2].

Given the guideline's position, most women will do better starting with a treatment that has stronger support (see the evidence section). If you still want to try it, a fair test is 3 months with a daily hot-flash diary.

In a 2005 double-blind trial, 64 menopausal women were randomised to two tablets of the Swedish pollen formula (sold as Femal) or placebo each morning for 3 months, and 54 completed it. 65% of the extract group had fewer hot flushes, compared with 38% on placebo (p<0.006); diary-recorded hot flushes fell 27% more than on placebo (p<0.026), and an overall rating of 15 other quality-of-life measures also favoured the extract [1].

A 2024 multicentre double-blind trial in Italy randomised 39 breast cancer survivors to the same purified pollen extract, as PureCyTonin (19 women), or placebo (20) for 3 months. On the extract, the number of hot flashes at 3 months was lower than at the start (p=0.02), and scores for hot-flash intensity, sweating, irritability and fatigue improved, but the abstract reports these as changes within the extract group rather than differences from placebo [2].

An open study of 104 menopausal women taking the same formula with vitamin E reported hot flashes 48.5% lower after 12 weeks [4]. An Italian study of 108 peri- and postmenopausal women found significant falls in hot flashes and night sweats after 3 months (both P<0.0001) [5]. Neither had a control group.

A non-randomised comparison followed 57 women on pollen extract, 60 on 60 mg soy isoflavones and 47 untreated for 6 months. At 6 months daily hot flashes had fallen 48.8% on pollen extract and 18.4% on isoflavones, and sleep quality improved more on pollen extract [12]. Because women were not randomised, these differences may reflect who took which product.

A 2024 systematic review found five eligible studies (one randomised trial and four observational studies, 420 women). Before-and-after scores improved sharply at 3 months (hot flashes, standardised mean difference -1.66), but pooling only the controlled studies left no statistically significant effect, and the authors concluded the improvements in uncontrolled studies may have been due to placebo [6]. An umbrella review of pollen research described the hot-flash evidence as preliminary [13].

The North American Menopause Society's 2023 statement reviewed the same trials and concluded that, based on expert opinion and limited research, pollen extract is not recommended (Level III) [7].

Hormone therapy remains the most effective treatment for hot flashes and should be considered by women within 10 years of their final period [7]. For women who can't use it, for example after an estrogen-dependent cancer, or who prefer not to, the society recommends cognitive behavioural therapy, clinical hypnosis, SSRIs or SNRIs, gabapentin and fezolinetant (Level I), and oxybutynin (Levels I-II). It does not recommend supplements or herbal remedies [7].

If you take tamoxifen, the choice of antidepressant matters: the society warns that SSRIs, particularly paroxetine and fluoxetine, can inhibit CYP2D6, the enzyme that converts tamoxifen to its most active metabolite, and names venlafaxine, desvenlafaxine, escitalopram and citalopram as safer choices [7].

The two controlled trials enrolled 64 and 39 women and lasted 3 months [1][2]. No trial has compared pollen extract with an established hot-flash treatment, and a review focused on women with breast cancer called for appropriately sized randomised trials [14].

Purified pollen extract appears well tolerated. The 2024 meta-analysis found it was not associated with significant adverse effects [6], the open study of 104 women reported a very low side-effect profile [4], and the trial in breast cancer survivors described it as well tolerated [2].

There are no data on use in pregnancy or breastfeeding, and none of the trials reported results separately for women with pollen allergies.

We found no interaction studies of pollen extract in people. In a laboratory test with human liver enzymes, it did not inhibit CYP2D6 at concentrations up to about five times the recommended daily dose [11]. That matters because some SSRIs, particularly paroxetine and fluoxetine, inhibit CYP2D6 in women using tamoxifen [7], which is why non-hormonal options are checked for this effect [11].